Pfizer Zyrtec corrective ad campaign demanded by Schering in false advertising suit.
PFIZER/UCB ZYRTEC CORRECTIVE AD CAMPAIGN SOUGHT BY SCHERING-PLOUGH in a lawsuit filed in Manhattan federal court Feb. 29. The suit charges Pfizer and UCB Pharma with promoting Zyrtec (cetirizine) to the medical community as "nonsedating" or "effectively nonsedating." Schering requests "an order directing Pfizer and UCB Pharma to disseminate corrective advertising to all doctors and health care providers or payors to whom Zyrtec has been promoted advising that Zyrtec is a sedating antihistamine and is not comparable to [Schering's] Claritin, [Hoechst Marion Roussel's] Seldane and [J&J's] Hismanal in its sedation effects."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth